IPOPLUS

₹1,411.1

▲ +34.6 +2.51%

17 Jun 2026

NSE Listed

Eris Lifesciences Limited (ERIS)

Volume: 63,719Avg Vol 1W: 53,764.6Avg Vol 1M: 1,76,070.1552W Range:₹1,200₹1,910
NSE BSE
₹1,411.1▲ 2.51%
Key Ratios
Updated 4h ago
Market Cap₹19,440 Cr
Current Price₹1,411.1
Previous Close₹1,376.5
High / Low (52w)₹1,910 / ₹1,200
Volume63,719
Avg Vol (1W)53,764.6
Avg Vol (1M)1,76,070.15
Stock P/E68.18
Book Value₹281.78
Dividend Yield0.5%
ROE15.9%
ROA8.8%
Revenue (TTM)₹2,912 Cr
Revenue Growth44%
Profit Margin19.9%
Total Debt₹1,738 Cr
Shares Outstanding14 Cr
Face Value₹1
EPS (TTM)₹20.6
P/B4.98
Debt / Equity0.6
50 DMA₹1,369.15
200 DMA₹1,490.21
Day change+2.51%
Price Chart
₹1,411.1▼ 21.21% · 1Y
₹1815₹127838.4L
2025-06-17
2026-06-12

20-day avg volume: 1.8L shares

Pros
  • Healthy return on equity of 15.9%.
  • Company is almost debt-free.
Cons
  • Revenue fell 11% YoY.
  • Stock trades at a high P/E of 68.
Quarterly Results
MetricJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue₹720 Cr₹741 Cr₹727 Cr₹705 Cr₹773 Cr₹792 Cr₹807 Cr₹757 Cr
EBITDA₹176 Cr₹189 Cr₹174 Cr₹183 Cr₹209 Cr₹222 Cr₹211 Cr₹206 Cr
Net Profit₹83 Cr₹92 Cr₹84 Cr₹94 Cr₹118 Cr₹120 Cr₹100 Cr₹282 Cr
EPS————————
Profit & Loss (Annual)
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹1,089 Cr₹1,221 Cr₹1,373 Cr₹1,696 Cr₹2,033 Cr₹2,912 Cr
EBITDA₹334 Cr₹396 Cr₹446 Cr₹431 Cr₹516 Cr₹720 Cr
Net Profit₹297 Cr₹355 Cr₹406 Cr₹382 Cr₹392 Cr₹352 Cr
EPS——————
Balance Sheet
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Total Assets₹1,552 Cr₹1,835 Cr₹2,272 Cr₹3,667 Cr₹7,040 Cr₹7,033 Cr
Total Liabilities₹256 Cr₹258 Cr₹364 Cr₹1,447 Cr₹3,818 Cr₹3,761 Cr
Equity₹1,296 Cr₹1,576 Cr₹1,908 Cr₹2,221 Cr₹3,222 Cr₹3,272 Cr
Total Debt₹0 Cr₹0 Cr₹45 Cr₹644 Cr₹655 Cr₹1,738 Cr
Cash Flow
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating₹323 Cr₹444 Cr₹462 Cr₹369 Cr₹587 Cr₹1,163 Cr
Investing₹123 Cr₹-323 Cr₹-320 Cr₹-982 Cr₹-1,855 Cr₹-80 Cr
Financing₹-335 Cr₹-82 Cr₹-45 Cr₹688 Cr₹1,380 Cr₹-881 Cr
Free Cash Flow₹323 Cr₹444 Cr₹462 Cr₹369 Cr₹587 Cr₹1,163 Cr

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search